Here are Thursday’s biggest analyst calls: Apple, Nvidia, Tesla, Alphabet, Kraft Heinz, Lyft, Palo Alto & more
Here are Thursday’s biggest calls on Wall Street: Goldman Sachs upgrades Sunbelt to buy from neutral Goldman said it sees “growth improvement.” “Our upgrade follows the strong 1Q27 results, which saw the company deliver results ahead of consensus while raising its FY outlook. SUNB has seen negative EPS growth for the last two years, owing to weakness in local non-resi construction markets in the US which has weighed on group revenue and margin.” Wolfe reiterates Tesla as peer perform Wolfe said the setup for Tesla is looking better for 2027 but is sticking with its peer perform rating. “Tesla – progress on key AI / Autonomy initiatives remains the key driver of the stock, with an increasingly attractive setup into 2027.” Bernstein downgrades Palo Alto Networks, Okta and SentinelOne to market perform from outperform Bernstein downgraded several cyber security stocks mainly on valuation. “based on the stock trading near fair value and equal upside/downside to the current trading range, we adjust Palo Alto Networks and Okta and SentinelOne to Market-Perform recommendations.” Citizens upgrades JBHT to market outperform from market perform Citizens said buy the weakness. “We are raising our rating on J.B. Hunt Transport Services (JBHT) shares from Market Perform to Market Outperform with a $300 price target.” Daiwa reiterates Nvidia as outperform Daiwa lowered its price target on Nvidia to $245 per share from $255. “Main issue near term is getting supply, long term is demand consistency” RBC initiates Kraft Heinz as outperform RBC said the company is well positioned for organic revenue growth. “We initiate coverage of Kraft Heinz at Outperform with a $32 PT.” Read more. Wells Fargo initiates Core Scientific, TeraWulf, Applied Digital and Hut 8 as overweight Wells initiated several bitcoin miners on Thursday and says they are compelling. “Our top picks are Overweight rated APLD, WULF and HUT (followed by CIFR + CORZ), which strike the right balance between NAV discounts, tenant credit quality and pipeline upside.” Barclays reinstates Paramount Skydance as underweight and Warner Bros Discovery as equal weight Barclays said it’s concerned that there is more corporate restructuring and M & A in the future. “This is why the investment case in PSKY may remain a bit of a moving target which will also make it more difficult for investors to articulate a valuation case to own the name despite significant long- term sum-of-the-parts optionality.” Raymond James initiates Red Violet as outperform Raymond James said the identity intelligence company has an “impressive fundamental backdrop.” “We are initiating coverage of Red Violet ( RDVT) with an Outperform rating as we see the combination of an impressive fundamental backdrop and a growing end market appetite for its more modern and accurate suite of identity intelligence offerings.” Bank of America reiterates Apple as buy The firm said demand for Apple’s iPhone should remain strong despite carrier subsidies. “While lead times indicate the iPhone 18 Pro and Pro Max shipment times are less extended vs last year the higher carrier subsidies could continue to support iPhone demand. Reiterate Buy on capital returns, eventual winner on AI at the edge and optionality from new products/markets.” Evercore ISI reiterates Alphabet as outperform Evercore raised its price target on Alphabet. “In the wake of our tenth proprietary Search survey, we are reiterating our Outperform rating, modestly raising our estimates, and raising our PT from $420 to $450, based on 25x our ’28 EPS of $18.11, which implies 30%+ upside from current levels Morgan Stanley initiates SiTime as overweight Morgan Stanley said buy the dip in shares of SiTime. “Following a ~13% pullback in the last week amid a broader semi sell-off, we see an attractive entry point. Initiate OW at $730 PT, ~33% upside.” Stifel initiates Roivant Sciences as buy Stifel said in its initiation of the biotech company that it has a “diversified late stage/ commercial pipeline with scarcity value in specialty markets.” “We are initiating coverage of ROIV with a Buy rating and $51 target price. JPMorgan initiates Celcuity as overweight JPMorgan said it’s bullish on the biotech company’s breast canter treatment. “We are initiating coverage of Celcuity (CELC) with an Overweight rating and a December 2027 price target of $157, reflecting the long-term potential of Revtorpyk (gedatolisib) in breast cancer.” Rosenblatt initiates Soluna Holdings as buy Rosenblatt said the bitcoin miner is well positioned. “We are initiating coverage of Soluna with a BUY rating and a $4 price target.” Jefferies initiates Alpha Teknova as buy Jefferies said in its initiation of Alpha Teknova that the biotech company best positioned for growth. “We see plenty of growth ahead, with upside tied to biotech funding (2H26 and beyond), recent commercial investment (early ’27) and clinical pipeline (2027+).” Citi upgrades Haemonetics to buy from neutral Citi said it sees growth upside for the medtech company. “We rate HAE a Buy. In a healthy Plasma market, the return of the CSL contract in the US market should provide upside to organic revenue growth, operating margins, and EPS over the next several years.” Macquarie upgrades Trip.com to outperform Macquarie said it sees improving global growth. “We believe TCOM ca n maintain a strong competitive position through international growth and its premium service offering. Upgrade to OP from N.” Oppenheimer initiates Kopin as outperform Oppenheimer said it sees “defense growth” for the electronics manufacturer. “We initiate coverage of Kopin with an Outperform rating and a $7 PT.” Susquehanna initiates Honeywell Aerospace as positive Susquehanna said the company is firing on all cylinders. “We believe HONA offers attractive revenue growth and margin expansion potential through the end of the decade and trades at a reasonable value compared to Aerospace & Defense peers.” Seaport initiates Paymentus as buy Seaport said the digital bill payment company has more room to run. “We are initiating coverage of Paymentus (PAY) with a Buy rating and $42 PT.” Guggenheim downgrades Lyft to neutral from buy. The firm said it sees a limited catalyst path. “We are downgrading LYFT from BUY to NEUTRAL with our $16 price target (vs. $22 prior) driven by our lower 2H-2027 volume forecasts coupled with limited sentiment catalyst path ahead.” Bank of America upgrades HawkEye 360 to buy from neutral Bank of America said the geospatial analytics company has an attractive valuation. “We are upgrading HawkEye 360 (HAWK) to Buy from Neutral while lowering our PO to $23 (vs. prior $34).” Truist initiates Crescent Energy as buy Truist said shares are compelling. “CRGY is a four-basin, acquisition-built oil producer that currently trades at just ~3.3x our ’27 EBITDAX vs peer median at ~4.1x, almost a 1-turn discount despite continued capital efficiency improvements alongside synergy capture post the Vital transaction.” JPMorgan initiates Prelude Therapeutics as overweight The firm said the biotech company has plenty of upside. We are initiating on Prelude Therapeutics (PRLD) with an Overweight rating and $12 December 2027 price target (PT).” Citi downgrades Boston Scientific to neutral from buy Citi said it was “saddened” to be downgrading the stock citing increased competition and a recent cyber attack. “For years, BSX has been a steady beat-and-raise stock, and while we are confident that it will work through this, the time to resolution is opaque, investor patience has run thin, and we don’t have a handle on the recovery path.”
About the Author
